🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,413 results for “ACE” Clear

  1. Niraparib tosylate monohydrate + abiraterone acetate - Film coated tablet- 79.90 mg (eq. 50mg base)+ 500mg, Capivasertib, NUBEQA 300 mg film-coated tablets, CABAZITAXEL, ENZALUTAMIDE , DAROLUTAMIDE , ABIRATERONE , ABIRATERONE ACETATE, APALUTAMIDE , RADIUM (223RA) DICHLORIDE , DOCETAXEL , OLAPARIB, Capivasertib, Niraparib tosylate monohydrate+ abiraterone acetate - Film coated tablet- 159.40 mg (eq. 100mg base)+ 500mg, BAY 1841788

    The George Institute

    Prostate Cancer

    phase 3 small molecule active

    1 trial

  2. NiuBangZi pill or NiuBangZi pill placebo

    Universal Integrated

    Niu Bang Zi Pill

    phase 3 small molecule active

    1 trial

  3. Nivolumab

    Ono Pharmaceutical Co.,

    Gastric Cancer

    phase 3 small molecule completed

    1 trial

  4. Nomlabofusp, Placebo to Nomlabofusp

    Larimar Therapeutics

    Friedreich’s ataxia is the most common inherited ataxia in humans and results from a deficiency of the mitochondrial protein, FXN. Friedreich’s ataxia is a rare, progressive, multisystem disease with an incidence that is estimated to be 1:29,000, and a carrier frequency of ~1:85.

    phase 3 small molecule active

    1 trial

  5. Nplate 500 micrograms powder for solution for injection, Placebo will be provided in identical 5 mL single-use vials as a sterile, white, preservative-free, lyophilized powder containing histidine, mannitol, sucrose, and polysorbate 20 and has a pH 5.0 when reconstituted with sterile water for injection., Nplate 500 micrograms powder for solution for injection

    Amgen

    Chemotherapy-induced Thrombocytopenia in Adult subjects with Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

    phase 3 small molecule active

    1 trial

  6. Nucala 100 mg powder for solution for injection, IMUREL 25 mg, comprimé pelliculé, CYCLOPHOSPHAMIDE, SODIUM CHLORIDE, PLACEBO D AZATHIOPRINE

    Pari Pharma GmbH

    Eosinophilic granulomatosis with polyangiitis (EGPA), formerly called Churg-Strauss syndrome

    phase 3 small molecule active

    1 trial

  7. OAV101

    Novartis Pharmaceuticals

    Spinal Muscular Atrophy

    phase 3 gene therapy completed

    1 trial

  8. OAV101B, Zolgensma 2 × 10^13 vector genomes/mL solution for infusion

    Novartis Pharmaceuticals

    Spinal Muscular Atrophy

    phase 3 small molecule active

    1 trial

  9. OCA IR 0.1 mg, 0,1 mg and 1,5 mg Placebo tablets, OCA 1.5 mg

    Lacuna Pharma Pty Ltd

    Biliary Atresia, Post-hepatoportoenterostomy

    phase 3 small molecule active

    1 trial

  10. OCRELIZUMAB, LOU064, OCRELIZUMAB

    Novartis Pharmaceuticals

    Relapsing multiple sclerosis

    phase 3 small molecule active

    1 trial

  11. OFC Infusion

    Novartis Pharmaceuticals

    Leukaemia, Lymphocytic, Chronic

    phase 3 small molecule completed

    1 trial

  12. ONDANSETRON ZYDUS 8 mg, comprimé orodispersible, Jakavi 5 mg tablets, EMEND 125 mg+80 mg hard capsules, Jakavi 15 mg tablets, Jakavi 20 mg tablets, PALONOSETRON, NETUPITANT, Akynzeo 300 mg/0.5 mg hard capsules, Selinexor placebo for 20 mg tablets formulated for oral administration., Jakavi 10 mg tablets, SELINEXOR, ONDANSETRON

    Karyopharm Therapeutics Inc

    Treatment naïve patients with MF

    phase 3 small molecule active

    1 trial

  13. ORFORGLIPRON, ORFORGLIPRON, ORFORGLIPRON, ORFORGLIPRON, Orforglipron, Placebo to match LY, ORFORGLIPRON

    Eli Lilly Co.

    Hypertension

    phase 3 small molecule active

    1 trial

  14. ORMD-0801

    ORAMED PHARMACEUTICALS INC.

    T2DM (Type 2 Diabetes Mellitus)

    phase 3 small molecule terminated

    1 trial

  15. ORMD-0801

    ORAMED PHARMACEUTICALS INC.

    Diabetes Mellitus, Type 2

    phase 3 small molecule active

    2 trials

  16. ORMD-0801 (qd)

    ORAMED PHARMACEUTICALS INC.

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    2 trials

  17. ORMD-0801 8 mg

    ORAMED PHARMACEUTICALS INC.

    Type 2 Diabetes Mellitus

    phase 3 small molecule active

    1 trial

  18. OXALIPLATIN , Placebo to MK-3475, CAPECITABINE , CALCIUM FOLINATE , FLUOROURACIL , CISPLATIN , KEYTRUDA 25 mg/mL concentrate for solution for infusion, DOCETAXEL

    Merck Sharp and Dohme

    Gastric and gastroesophageal junction (GEJ) adenocarcinoma

    phase 3 small molecule active

    1 trial

  19. OXALIPLATIN, Bemarituzumab, Placebo for AMG 552, FLUOROURACIL, FOLINIC ACID

    Amgen

    Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b overexpression

    phase 3 small molecule active

    1 trial

  20. Ocrevus 300 mg concentrate for solution for infusion, Paracetamol 500mg Tablets, Methylprednisolone 500 mg powder and solvent for solution for injection/infusion, Placebo ocrelizumab, Diphenhydramine Hydrochloride Tablets 50 mg, Ocrevus 300 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Relapsing Multiple Sclerosis (MS)

    phase 3 small molecule active

    1 trial

  21. Ofatumumab

    Novartis Pharmaceuticals

    Leukaemia, Lymphocytic, Chronic

    phase 3 mab terminated

    1 trial

  22. Olaparib, ETOPOSIDE , KEYTRUDA 25 mg/mL concentrate for solution for infusion, Pembrolizumab placebo (saline), Olaparib matching placebo (tablet), CARBOPLATIN , CISPLATIN , Olaparib

    Merck Sharp and Dohme

    Participants with Limited Stage-Small Cell Lung Cancer, who have received no prior anticancer therapy for their disease.

    phase 3 small molecule active

    1 trial

  23. Olezarsen

    IONIS PHARMACEUTICALS INC

    Severe Hypertriglyceridemia

    phase 3 small molecule completed

    3 trials

  24. Olezarsen

    IONIS PHARMACEUTICALS INC

    Familial Chylomicronemia Syndrome

    phase 3 small molecule active

    3 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources